Zarazne bolesti – pitajte doktora
Postavite pitanje o simptomima, dijagnozi ili terapiji. Odgovor lekara je potpuno besplatan. Već 6305 pitanja iz oblasti Zarazne bolesti.
Da zakažete pregled pozovite 063 687 460
Lekari iz ove oblasti
Svi odgovori (6305)
dovoljna je vakcina, a imuglobulin se daje nevakcinisanim, a vi ste kao dete vakcinisani i naravno da se ne sećate
multirezistentni S.aureus, najčešće je intrahospitalna infekcija, u zavisnosti od organa, ili tkiva koje je zahvaćeno, postoji lečenje.Evo u prilogu tekst iz udžbnika
MRSA isolates have become common, especially in hospitals. MRSA are resistant to all beta-lactam antibiotics, including cephalosporins and carbapenems; however, they may be susceptible to the newest class of MRSA-active cephalosporins (eg, ceftaroline, ceftobiprole [not available in the US]). Hospital-acquired MRSA are also commonly resistant to many other antibiotics, including erythromycin, clindamycin, and fluoroquinolones. In addition, community-associated MRSA (CA-MRSA) has emerged over the past several years in most geographic regions. CA-MRSA tends to be less resistant to multiple drugs than hospital-acquired MRSA. These strains, although resistant to most beta-lactams, are usually susceptible to TMP/SMX and tetracyclines (minocycline, doxycycline) and are often susceptible to clindamycin, but there is the potential for emergence of clindamycin resistance by strains inducibly resistant to erythromycin (laboratories may report these strains as D-test positive). Vancomycin is effective against most MRSA, sometimes with rifampin and an aminoglycoside added for some serious infections (ie, osteomyelitis, prosthetic joint infections, prosthetic valve endocarditis). An alternative drug (daptomycin, linezolid, tedizolid, dalbavancin, oritavancin, telavancin, tigecycline, omadacycline, lefamulin, eravacycline, delafloxacin, quinupristin/dalfopristin, TMP/SMX, possibly ceftaroline) should be considered when treating MRSA strains with a vancomycin minimum inhibitory concentration (MIC) of ≥ 1.5 mcg/mL.
Vancomycin-resistant S. aureus (VRSA; MIC ≥ 16 mcg/mL) and vancomycin-intermediate-susceptible S. aureus (VISA; MIC 4 to 8 mcg/mL) strains have appeared in the US. These organisms require linezolid, tedizolid, quinupristin/dalfopristin, daptomycin, TMP/SMX, delafloxacin, oritavancin, or ceftaroline. Dalbavancin and telavancin are active against VISA but have little activity against VRSA.
Because incidence of MRSA has increased, initial empiric treatment for serious staphylococcal infections (particularly those that occur in a health care setting) should include a drug with reliable activity against MRSA. Thus, appropriate drugs include the following:
-
For proven or suspected bloodstream infections, vancomycin or daptomycin
-
For pneumonia, vancomycin, telavancin, or linezolid (because daptomycin is not reliably active in the lungs)
Table
MRSA isolates have become common, especially in hospitals. MRSA are resistant to all beta-lactam antibiotics, including cephalosporins and carbapenems; however, they may be susceptible to the newest class of MRSA-active cephalosporins (eg, ceftaroline, ceftobiprole [not available in the US]). Hospital-acquired MRSA are also commonly resistant to many other antibiotics, including erythromycin, clindamycin, and fluoroquinolones. In addition, community-associated MRSA (CA-MRSA) has emerged over the past several years in most geographic regions. CA-MRSA tends to be less resistant to multiple drugs than hospital-acquired MRSA. These strains, although resistant to most beta-lactams, are usually susceptible to TMP/SMX and tetracyclines (minocycline, doxycycline) and are often susceptible to clindamycin, but there is the potential for emergence of clindamycin resistance by strains inducibly resistant to erythromycin (laboratories may report these strains as D-test positive). Vancomycin is effective against most MRSA, sometimes with rifampin and an aminoglycoside added for some serious infections (ie, osteomyelitis, prosthetic joint infections, prosthetic valve endocarditis). An alternative drug (daptomycin, linezolid, tedizolid, dalbavancin, oritavancin, telavancin, tigecycline, omadacycline, lefamulin, eravacycline, delafloxacin, quinupristin/dalfopristin, TMP/SMX, possibly ceftaroline) should be considered when treating MRSA strains with a vancomycin minimum inhibitory concentration (MIC) of ≥ 1.5 mcg/mL.
Vancomycin-resistant S. aureus (VRSA; MIC ≥ 16 mcg/mL) and vancomycin-intermediate-susceptible S. aureus (VISA; MIC 4 to 8 mcg/mL) strains have appeared in the US. These organisms require linezolid, tedizolid, quinupristin/dalfopristin, daptomycin, TMP/SMX, delafloxacin, oritavancin, or ceftaroline. Dalbavancin and telavancin are active against VISA but have little activity against VRSA.
Because incidence of MRSA has increased, initial empiric treatment for serious staphylococcal infections (particularly those that occur in a health care setting) should include a drug with reliable activity against MRSA. Thus, appropriate drugs include the following:
-
For proven or suspected bloodstream infections, vancomycin or daptomycin
-
For pneumonia, vancomycin, telavancin, or linezolid (because daptomycin is not reliably active in the lungs)
Table
MRSA isolates have become common, especially in hospitals. MRSA are resistant to all beta-lactam antibiotics, including cephalosporins and carbapenems; however, they may be susceptible to the newest class of MRSA-active cephalosporins (eg, ceftaroline, ceftobiprole [not available in the US]). Hospital-acquired MRSA are also commonly resistant to many other antibiotics, including erythromycin, clindamycin, and fluoroquinolones. In addition, community-associated MRSA (CA-MRSA) has emerged over the past several years in most geographic regions. CA-MRSA tends to be less resistant to multiple drugs than hospital-acquired MRSA. These strains, although resistant to most beta-lactams, are usually susceptible to TMP/SMX and tetracyclines (minocycline, doxycycline) and are often susceptible to clindamycin, but there is the potential for emergence of clindamycin resistance by strains inducibly resistant to erythromycin (laboratories may report these strains as D-test positive). Vancomycin is effective against most MRSA, sometimes with rifampin and an aminoglycoside added for some serious infections (ie, osteomyelitis, prosthetic joint infections, prosthetic valve endocarditis). An alternative drug (daptomycin, linezolid, tedizolid, dalbavancin, oritavancin, telavancin, tigecycline, omadacycline, lefamulin, eravacycline, delafloxacin, quinupristin/dalfopristin, TMP/SMX, possibly ceftaroline) should be considered when treating MRSA strains with a vancomycin minimum inhibitory concentration (MIC) of ≥ 1.5 mcg/mL.
Vancomycin-resistant S. aureus (VRSA; MIC ≥ 16 mcg/mL) and vancomycin-intermediate-susceptible S. aureus (VISA; MIC 4 to 8 mcg/mL) strains have appeared in the US. These organisms require linezolid, tedizolid, quinupristin/dalfopristin, daptomycin, TMP/SMX, delafloxacin, oritavancin, or ceftaroline. Dalbavancin and telavancin are active against VISA but have little activity against VRSA.
Because incidence of MRSA has increased, initial empiric treatment for serious staphylococcal infections (particularly those that occur in a health care setting) should include a drug with reliable activity against MRSA. Thus, appropriate drugs include the following:
-
For proven or suspected bloodstream infections, vancomycin or daptomycin
-
For pneumonia, vancomycin, telavancin, or linezolid (because daptomycin is not reliably active in the lungs)
ja sam u penziji već 4 godine i nikoga nisam otpuštao, te s tim slučajem nisam nikako povezan
posleoko 8 nedelja, a dosta ranije je pouzdan test na virusnu DNK, odnosno RNK, PCR tehnikom
podoksifilin 0.5% gel jecefikasan. mazati 2x dnevno, 2x dnevno mazati 3 dana, pa 4. dan pauza, pa sve ponoviti 4 puta
ponovna vakcina mu neće nauditi
nije potrebno ponavljati veš vičestruko negativne testove
malo verovatno, a najjednostavnije je da se partner testira na HIV
sve to zajedno nema veze sa bilo kakvim hepatitiso, idite kod infektologa na pregled
kod oko 10% inficiranih nastupa spontano izlečenje, ali većina pređe u hroničnu infekciju.Potrebno je posle oko meseci od akutne faze proveriti HCVRNK PCR zestom
ne je značilo da ništa više nije potrebno, a bol u leđima nije povezan sa seksualno prenosivim infekcijama
probajte dijetu sa hranom koja pospešuje defekaciju- suve šljive u kompotu, više tečnosti- supe, čorbe od povrća
ipak, trebalo bi proverite testove na hepatitise B i C
doksiciklin 100 mg na 12 h, 7 dana